CASI Pharmaceuticals, Inc. · OTC:CASIF
CASI Pharmaceuticals — BIO CEO & Investor Conference 2018
18 slides from CASI Pharmaceuticals's conference presentation, Feb 13, 2018

Slide 1: Corporate Presentation – BIO CEO & Investor Conference
Corporate Presentation BIO CEO & INVESTOR CONFERENCE New York, NY February 13, 2018

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward- looking statemen

Slide 3: Mission
Mission To Build an Integrated Pharmaceutical Company Serving 1.5 billion People in China with High Quality and Affordable Products while Addressing the U.S. and Global Markets Cost-Effectively Slide 3

Slide 4: Acquisition from Sandoz: 29 ANDA Products and Pipeline
Acquisition from Sandoz 29 ANDA Products and Pipeline 25 FDA Approved, 4 Pending FDA Approval ANDAs Diverse Portfolio Across Attractive Therapeutic Area 12% 35% 19% 15% 8% 11% Hypertension/PVD Metabolic Disorders CNS Anti-infectious Anti-inflammatory/pain Others Slide 4

Slide 5: Historical Opportunity for FDA-Approved ANDAs in China
Historical Opportunity for FDA-Approved ANDAs in China Rapidly Establishing A Lead Position in China’s >$100 bn Small Molecule Drug Market Rapid Entry Technology Barriers, Opportunity for Industry Consolidations CFDA’s Bio- CFDA’s BE Waiver on FDA ANDA Equivalence China Products Re-Evaluation of All

Slide 6: Value Proposition
Value Proposition China, America, Synergy, Integration A Unique Competitive Position to Capitalize the Opportunity Cost-Pricing Pressure Government Initiatives Players Exit Generics Industry Consolidation Market Needs Market Needs - Advanced Technology - Fast Growing Market - Science and Innovation

Slide 7: ANDA Development Strategy and Plan
ANDA Development Strategy and Plan Self-Development and Partnering with Local Players Year 1 Year 2 In the U.S. FDA File FDA FDA ANDA Re-launch Approved CBE-30 or Modification ANDA products ANDAs PAS Approval in the U.S. Technology FDA/CFDA cGMP Manufacturing In China Transfer to Launch CMO in in Ch

Slide 8: A Platform for Pursuing Additional Product Pipeline Portfolio
A Platform for Pursuing Additional Product Pipeline Portfolio On the Top List in China with FDA ANDA Products and Pipeline with Opportunity for Rapid Growth Greater China Rights FDA ANDAs Acquired From SPPI ENMD-2076, Global Rights Acquired From Sandoz 25 FDA Approved ANDAs Innovative Drug Candidate

Slide 9: China Market for Zevalin, Marqibo, Evomela
China Market for ZEVALIN®, MARQIBO®, EVOMELA™ • Strong IP position, greater China exclusivity, and significant technology barriers • Minimal clinical, regulatory, and financial risks as they are all FDA approved products, already sold in the U.S. • The value of each of the products will increase inc

Slide 10: The Market Potential in China (Evomela)
The Market Potential in China • No form of melphalan, branded or generic, is currently available in China – EVOMELA will address an urgent medical need • CASI’s import drug application for EVOMELA was granted priority review by the China FDA, acknowledging the urgent medical need and EVOMELA’s thera

Slide 11: The Market Potential in China (Marqibo)
The Market Potential in China • Proprietary liposomal formulation of vincristine which improves the pharmacokinetics and pharmacodynamics of vincristine* – Higher maximum tolerated dose, superior antitumor activity and delivered higher amounts of active drug to target tissues • Annual incidence of l

Slide 12: The Market Potential in China (Zevalin)
The Market Potential in China • Anti-CD20 antibody coupled to Yttrium-90 ̶ 83% ORR, 39% CR in relapsed or refractory, low-grade or follicular B-cell NHL • Annual incidence of NHL in China is estimated at 83,790 new cases with a mortality of 50,100 cases in 2015*. • ZEVALIN is expected to rapidly pen

Slide 13: Market for Entecavir
Market for Entecavir • Hepatitis B virus (HBV) infection remains a severe public health problem worldwide, with 2 billion people currently infected, 360 million having chronic infections and 600,000 deaths annually from either HBV-related liver disease or hepatocellular carcinoma.* • In China, about

Slide 14: China Market for 6 Key ANDA Products
China Market for 6 Key ANDA Products Key Products by 2016 (Estimated) Generic Sales in China Product Indication 2016E Sales (in US$) 1 Entecavir tablet HBV Infection 1,490,000,000 2 Repaglinide tablet Diabetes 225,000,000 3 Bisoprolol Fumarate tablet Hypertension 205,000,000 4 Cilostazol tablet peri

Slide 15: U.S. Market for the Key ANDA Products
U.S. Market for the 8 Key ANDA Products Key Products by 2016 U.S. Sales* Product Name Indications Sandoz U.S. Sales Overall U..S Generic 2016 (IMS data) Sales 2016 (IMS data) 1 Midodrine Hypotension 19,800,000 56,900,000 2 Triamterene / HCTZ cap Hypertension, diuretic 4,600,000 54,000,000 3 Lisinopr

Slide 16: On Fast Track for Growth and Expansion
On Fast Track for Growth and Expansion Partnership Expansion Commercialization Acquisition Product Pipeline Internal Growth Slide 16

Slide 17: Investment Highlights
Investment Highlights • Market: Well-positioned to pursue significant and unprecedented market opportunities in China and the U.S. • Model: Compelling business model with important U.S./China synergies and competitive advantage with efficiency and cost-effectiveness for drug development and commerci

Slide 18: NASDAQ: CASI
NASDAQ: CASI www.casipharmaceuticals.com Slide 18
Source: Internet Archive copy of casipharmaceuticals.com
More decks from CASI Pharmaceuticals, Inc.
Investor Presentation (January 2026)28 slides · January 2026
Corporate Update (May 2025)21 slides · May 21, 2025
Investor Presentation (August 2022)30 slides · August 2022
Investor Presentation (May 2022)30 slides · May 2022
Jefferies London Healthcare Conference 202129 slides · November 2021
Investor Presentation (September 2021)21 slides · September 2021